| Literature DB >> 16036074 |
Abstract
Bisphosphonates are effective inhibitors of bone remodeling. In the clinical setting, these agents prevent bone loss, preserve bone architecture, and improve bone strength. Clinically significant reduction in the risk of spine and nonspine fractures is observed in patients known to be at risk for fracture. When administered appropriately, these drugs are well tolerated and have an excellent safety profile. Potent bisphosphonates are now the preferred treatment option to reduce the fracture risk in men and women with involutional and glucocorticoid-induced osteoporosis.Entities:
Mesh:
Substances:
Year: 2003 PMID: 16036074 DOI: 10.1007/s11914-996-0006-5
Source DB: PubMed Journal: Curr Osteoporos Rep ISSN: 1544-1873 Impact factor: 5.096